LH
Labcorp Holdings Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Next Twelve Months Forecast Backlog Conversion | $2.69B | As of March 31 | — |
| TTM Book to Bill | 1.04 | As of March 31 | — |
| TTM Net Orders | $3.29B | As of March 31 | — |
| Total Price/Mix Delta | 3.3% | Q4 | — |
| Total Volume Delta | 2.2% | Q4 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LH
this stock
Labcorp Holdings Inc.
|
$23.53B | +14.7% | +7.2% | 25.4 | 4.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$194.52B | -9.6% | +0.4% | 28.8 | 1.2% |
|
DHR
Danaher Corp /De/
|
$140.09B | -13.4% | +8.5% | 38.2 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.00B | -17.5% | +10.4% | 41.0 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.00B | +21.9% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LH | +7.8% | +10.8% | +13.0% | +2.5% | +14.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +6.3% | +12.1% | +5.0% | +2.8% | +5.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.